S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

Kura Oncology (KURA) Competitors

$21.76
+1.02 (+4.92%)
(As of 02/27/2024 ET)

KURA vs. ABCL, SUPN, AGIO, PTGX, IRON, DVAX, PRTA, CPRX, XNCR, and KNSA

Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include AbCellera Biologics (ABCL), Supernus Pharmaceuticals (SUPN), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Disc Medicine (IRON), Dynavax Technologies (DVAX), Prothena (PRTA), Catalyst Pharmaceuticals (CPRX), Xencor (XNCR), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.

Kura Oncology vs.

AbCellera Biologics (NASDAQ:ABCL) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, AbCellera Biologics had 25 more articles in the media than Kura Oncology. MarketBeat recorded 40 mentions for AbCellera Biologics and 15 mentions for Kura Oncology. AbCellera Biologics' average media sentiment score of 0.77 beat Kura Oncology's score of 0.38 indicating that Kura Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbCellera Biologics
7 Very Positive mention(s)
3 Positive mention(s)
14 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kura Oncology
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AbCellera Biologics presently has a consensus target price of $15.86, indicating a potential upside of 209.71%. Kura Oncology has a consensus target price of $28.28, indicating a potential upside of 29.95%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe AbCellera Biologics is more favorable than Kura Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kura Oncology
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Kura Oncology has a net margin of 0.00% compared to Kura Oncology's net margin of -384.99%. Kura Oncology's return on equity of -12.36% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbCellera Biologics-384.99% -12.36% -9.70%
Kura Oncology N/A -33.54%-30.90%

AbCellera Biologics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

47.4% of AbCellera Biologics shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by insiders. Comparatively, 5.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kura Oncology has lower revenue, but higher earnings than AbCellera Biologics. Kura Oncology is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera Biologics$38.03M39.42-$146.40M-$0.52-9.85
Kura OncologyN/AN/A-$135.84M-$2.02-10.77

Kura Oncology received 344 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.92% of users gave AbCellera Biologics an outperform vote while only 68.76% of users gave Kura Oncology an outperform vote.

CompanyUnderperformOutperform
AbCellera BiologicsOutperform Votes
50
76.92%
Underperform Votes
15
23.08%
Kura OncologyOutperform Votes
394
68.76%
Underperform Votes
179
31.24%

Summary

AbCellera Biologics beats Kura Oncology on 12 of the 17 factors compared between the two stocks.


Get Kura Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KURA vs. The Competition

MetricKura OncologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.58B$6.73B$5.02B$7.50B
Dividend YieldN/A2.80%2.90%3.88%
P/E Ratio-10.777.37176.3813.41
Price / SalesN/A169.373,189.2864.11
Price / CashN/A19.0494.5554.62
Price / Book3.464.834.504.68
Net Income-$135.84M$153.01M$111.98M$210.78M
7 Day Performance8.85%6.59%5.32%2.96%
1 Month Performance21.02%13.97%13.36%5.38%
1 Year Performance82.55%6.34%13.40%8.21%

Kura Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABCL
AbCellera Biologics
1.6213 of 5 stars
$5.31
-0.6%
$20.38
+283.7%
-39.3%$1.54B$485.42M-11.80630Analyst Revision
SUPN
Supernus Pharmaceuticals
4.5299 of 5 stars
$28.05
-1.3%
$43.00
+53.3%
-19.2%$1.53B$667.24M68.42612News Coverage
AGIO
Agios Pharmaceuticals
1.8712 of 5 stars
$27.10
+2.2%
$34.00
+25.5%
+37.8%$1.52B$26.82M-4.27389
PTGX
Protagonist Therapeutics
1.5422 of 5 stars
$27.23
-2.9%
$35.25
+29.5%
+81.9%$1.57B$26.58M-10.39111
IRON
Disc Medicine
0.2107 of 5 stars
$66.42
+0.8%
$64.56
-2.8%
+171.6%$1.60BN/A0.0060
DVAX
Dynavax Technologies
4.5414 of 5 stars
$12.28
-1.0%
$25.00
+103.6%
+25.4%$1.60B$361.18M31.49351Analyst Revision
PRTA
Prothena
4.0258 of 5 stars
$27.53
-1.7%
$69.89
+153.9%
-44.5%$1.48B$91.37M-9.83127Gap Up
CPRX
Catalyst Pharmaceuticals
4.9332 of 5 stars
$13.79
-1.5%
$25.80
+87.1%
-6.7%$1.62B$214.20M26.5282News Coverage
XNCR
Xencor
3.6036 of 5 stars
$23.50
-2.7%
$40.38
+71.8%
-19.3%$1.43B$164.58M-11.81281
KNSA
Kiniksa Pharmaceuticals
0.8615 of 5 stars
$19.92
-0.1%
$22.50
+13.0%
+56.8%$1.40B$220.18M-181.07220Positive News

Related Companies and Tools

This page (NASDAQ:KURA) was last updated on 2/28/2024 by MarketBeat.com Staff